Degludec Glargine U300 Hospital Study

NACompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Type 2 Diabetes
Interventions
DRUG

Degludec

Treatment with insulin degludec when compared to insulin glargine U-300 will result in similar blood glucose control in hospitalized patients with type 2 diabetes.

DRUG

Glargine U300

Treatment with insulin glargine U300 when compared to insulin degludec will result in similar blood glucose control in hospitalized patients with type 2 diabetes.

Trial Locations (1)

122001

Division Of Endocrinology and Diabetes , Medanta The Medicity Hospital, Gurgaon

All Listed Sponsors
lead

Medanta, The Medicity, India

OTHER

NCT05036876 - Degludec Glargine U300 Hospital Study | Biotech Hunter | Biotech Hunter